Fifty-eight patients had drug allergy, including 50 patients having allergic reactions to one kind of drug, six patients to two kinds of drugs and two patients to three kinds of drugs.

<p>The two numbers indicate the number and percentage of patients.</p

Association between type of allergic drug and lymph node metastasis.

<p>CI: confidence intervals; LNM: lymph node metastasis; OR: odds ratios.</p><p>*Of the 58 patients with drug allergy, six patients had allergic reactions to two kinds of drugs and two patients had reactions to three kinds of drugs. Their ORs and 95% CIs were calculated using Pearson Chi-Square tests.</p><p>Association between type of allergic drug and lymph node metastasis.</p

Univariate analysis showed that the percentage of drug allergy was lower in rectal adenocarcinoma (RAC) patients with pathological lymph node metastasis (pLNM) compared with those patients without pLNM (8.7% vs. 16.0%, P = 0.016).

<p>Univariate analysis showed that the percentage of drug allergy was lower in rectal adenocarcinoma (RAC) patients with pathological lymph node metastasis (pLNM) compared with those patients without pLNM (8.7% vs. 16.0%, P = 0.016).</p

Association between drug allergy and clinicopathological data.

<p>Association between drug allergy and clinicopathological data.</p

Basic characteristics of 469 patients with rectal adenocarcinoma (RAC).

<p>BMI, body mass index; LNM, lymph node metastasis; RAC, rectal adenocarcinoma.</p><p>Data were available in^a403 (202+201), ^b463 (227+236), ^c457 (226+231), ^d392 (192+200) and ^e370 (178+192) patients. The numbers before the brackets indicate the total available cases in the two groups.</p><p>*Plus-minus value indicates mean±standard deviation;</p>†<p>Median (inter-quartile range, Q1– Q3).</p><p>Basic characteristics of 469 patients with rectal adenocarcinoma (RAC).</p

Pathological characteristics and follow-up results of 469 RAC patients.

†<p>Median (inter-quartile range, Q1–Q3).</p><p>Pathological characteristics and follow-up results of 469 RAC patients.</p

Multivariate analysis for drug allergy and the risk of lymph node metastasis^*.

<p>CI: confidence intervals; OR: odds ratios.</p><p>*457 patients were included because the data were not available for 12 patients. Carcinoembryonic antigen (CEA) was excluded because those were not available in 77 patients and preliminary results showed that CEA was not associated with LMN by multivariate analysis in our patients.</p><p>Multivariate analysis for drug allergy and the risk of lymph node metastasis^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0106123#nt107" target="_blank">*</a>}.</p

Survival analysis: Kaplan-Meier curve (log rank test) showed lymph node metastasis was associated with the prognosis (survival time).

<p>Survival analysis: Kaplan-Meier curve (log rank test) showed lymph node metastasis was associated with the prognosis (survival time).</p

E-cadherin and DAB2IP expression in normal gastric mucosa, primary gastric tumors and Metastasis V within the mesogastrium.

<p>(A) Representative IHC staining for DAB2IP and E-cadherin from the same patient. (B) The relative quantitative analysis of E-cadherin and DAB2IP expression. One asterisk indicated statistical significance in normal mucosa vs. primary tumors (*, P < 0.01). Two asterisks indicated statistical significance in primary tumors vs. mesogastrium (**, P<0.01).</p

Clinicopathological data of patients with Metastasis V.

<p>Por: poorly differentiated adenocarcinoma, Mod: moderately differentiated adenocarcinoma.</p><p>Clinicopathological data of patients with Metastasis V.</p